Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. Summary
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
13.91(c) 13.5(c) 13.34(c) 13.18(c) 13.21(c) Last
65 281 37 710 45 922 33 659 21 425 Volume
-4.14% -2.95% -1.19% -1.20% +0.23% Change
More quotes
Financials
Sales 2021 2,05 M 2,47 M 2,47 M
Net income 2021 -39,9 M -48,3 M -48,3 M
Net cash position 2021 67,4 M 81,6 M 81,6 M
P/E ratio 2021 -9,17x
Yield 2021 -
Sales 2022 2,74 M 3,32 M 3,32 M
Net income 2022 -46,6 M -56,5 M -56,5 M
Net cash position 2022 47,1 M 57,1 M 57,1 M
P/E ratio 2022 -9,02x
Yield 2022 -
Capitalization 460 M 556 M 557 M
EV / Sales 2021 192x
EV / Sales 2022 151x
Nbr of Employees 89
Free-Float 94,1%
More Financials
Company
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the local treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without... 
More about the company
Ratings of Nanobiotix
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NANOBIOTIX
06/08NANOBIOTIX  : TO HOST VIRTUAL KOL EVENT DISCUSSING POTENTIAL FIRST-IN-CLASS RADI..
PU
06/08GLOBAL MARKETS LIVE : Apple, Nvidia, Biogen, Fastly, Tilray...
06/07NANOBIOTIX  : to Host Virtual KOL Event Discussing Potential First-in-Class Radi..
BU
06/04NANOBIOTIX  : REPORTS NEW DATA FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3..
PU
06/04NANOBIOTIX  : Cancer Combo Therapy Shrinks Tumor in Early-Stage Study
MT
06/03NANOBIOTIX  : Reports New Data for Potential First-in-Class Radioenhancer NBTXR3..
BU
06/02GLOBAL MARKETS LIVE : Tesla, AB Volvo, Credit Suisse, Amazon, Tyson Foods...
06/02NANOBIOTIX  : CFO Steps Down, Successor Named
MT
06/01NANOBIOTIX  : ANNOUNCES THE APPOINTMENT OF BART VAN RHIJN AS CHIEF FINANCIAL OFF..
PU
06/01NANOBIOTIX S A  : Hires Bart Van Rhijn as CFO
MT
06/01NANOBIOTIX  : Announces the Appointment of Bart Van Rhijn as Chief Financial Off..
BU
05/27NANOBIOTIX  : TO PARTICIPATE IN FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCAR..
PU
05/26NANOBIOTIX  : to Participate in Fireside Chat at the Jefferies Virtual Healthcar..
BU
05/26GLOBAL MARKETS LIVE : Amazon, Volkswagen, AstraZeneca, Aston Martin, Sony...
05/26NANOBIOTIX S A  : Names Gary Phillips as Supervisory Board Chairman
MT
More news
News in other languages on NANOBIOTIX
06/08STOCK MARKET PARIS : La pente est faible, mais la route est droite
06/08Les valeurs à suivre aujourd'hui à Paris Mardi 8 juin 2021
06/08NANOBIOTIX  : discussion virtuelle entre experts autour du NBTXR3 vendredi
06/08EN DIRECT DES MARCHES  : Airbus, Alstom, Safran, EDF, Solutions 30, Apple, Nvidi..
06/07NANOBIOTIX  : Organise une discussion virtuelle entre experts sur les nouvelles ..
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 25,30 €
Last Close Price 13,21 €
Spread / Highest target 218%
Spread / Average Target 91,5%
Spread / Lowest Target -0,08%
EPS Revisions
Managers and Directors
NameTitle
Laurent Lévy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Alain Dostie Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
NANOBIOTIX-4.28%556
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416